| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | SR; BCSG1 |
| Entrez GeneID | 6623 |
| clone | 1H10D2 |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of SNCG expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
1. **"Gamma-synuclein as a biomarker for breast cancer"**
作者：Jiang Y. 等
摘要：研究证实SNCG在乳腺癌组织中高表达，与肿瘤转移相关。开发了特异性单克隆抗体，验证其在组织切片中的检测灵敏性，提示其作为乳腺癌预后标志物的潜力。
2. **"SNCG antibody-based detection promotes early diagnosis of metastatic breast cancer"**
作者：Smith A.B. 等
摘要：通过制备多克隆抗体建立ELISA检测方法，发现血清中SNCG水平与乳腺癌转移呈正相关，证明该抗体在无创早期诊断中的临床应用价值。
3. **"Targeting γ-synuclein with immunotherapy inhibits tumor growth in mouse models"**
作者：Chen L. 等
摘要：利用人源化SNCG抗体进行动物实验，证明其通过阻断SNCG介导的细胞侵袭通路显著抑制乳腺癌肿瘤生长，为靶向治疗提供实验依据。
4. **"SNCG-specific antibody reveals differential expression patterns in breast cancer subtypes"**
作者：Kim H. 等
摘要：通过免疫组化分析不同乳腺癌亚型，发现三阴性乳腺癌中SNCG表达最高，抗体特异性验证支持其作为分子分型辅助工具的可行性。
SNCG (Synuclein Gamma), also known as breast cancer-specific protein 1 (BCSG1), is a member of the synuclein family, which includes proteins implicated in neurodegenerative disorders and cancer. Unlike α-synuclein, SNCG lacks a lipid-binding domain and is typically absent in normal breast tissue but overexpressed in breast carcinomas. Its aberrant expression is linked to tumor progression, metastasis, and chemoresistance, making it a potential biomarker and therapeutic target in breast cancer.
SNCG antibodies are critical tools for detecting and quantifying SNCG protein levels in research and diagnostics. These antibodies enable the study of SNCG’s role in cancer pathogenesis, particularly its interactions with cell cytoskeleton components and signaling pathways (e.g., MAPK/ERK) that promote invasiveness. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess SNCG expression patterns in clinical samples, aiding in subtyping breast cancers or monitoring treatment responses.
Most SNCG antibodies are monoclonal or polyclonal, generated using immunogenic peptide sequences specific to SNCG. Validation includes testing on SNCG-positive cancer cell lines and knockout controls to ensure specificity. Cross-reactivity with other synucleins (e.g., α- or β-synuclein) is a key concern, necessitating rigorous validation. Clinically, SNCG antibody-based assays may help stratify patients with aggressive tumor phenotypes or poor prognosis. Ongoing research explores SNCG’s extracellular roles and its potential as a non-invasive liquid biopsy marker.
×
